medigraphic.com

2011, Number 1

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2011; 49 (1)

The epileptic syndromes in childhood

Alva-Moncayo E

Language: Spanish
References: 26
Page: 37-44
PDF size: 108.38 Kb.


ABSTRACT

Background: the epileptic syndrome in childhood was described by The International League against Epilepsy (ILAE) for the evaluation and understanding purpose. They defined epilepsy, clinical symptoms and paraclinic manifestations, in relation with the age of onset and prognostic determinants. The etiological classification included the symptomatic group, when it is identify a causal, cryptogenic without a cause and idiopathic when we only have hereditary antecedents and we do not know the cause. The treatment is based on type of seizures, experience and clinical evidence. But always is important and a need to know the adverse effects and how to use three antiepileptic drugs or more. The objective it is to describe the classification, a diagnostic, therapeutic and prognostic guide. The more frequent epileptic syndromes included: the neonatal group with Ohtahara syndrome, and neonatal symptomatic seizures. Infant group included the West and Dravet syndromes, Lennox Gastaut syndrome, and brain absences. The scholar group: juvenile myoclonic epilepsy and centre-temporal syndrome as the most representative. We classify in relation to anatomical localization and etiology. We need to know therapeutic dose, pharmacological interactions and contraindications of the antiepileptic drugs.


REFERENCES

  1. Placencia M. Incidencia, prevalencia y magnitud global de las epilepsias. En: Campos MG, Kanner AM, editores. Epilepsias: diagnóstico y tratamiento. Santiago de Chile: Mediterráneo; 2004. p. 49-77.

  2. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22(4):489-501.

  3. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-399.

  4. Engel J Jr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification an Terminology. Epilepsia 2001;42(6):796-803.

  5. Engel J Jr. ILAE classification of epilepsy syndromes. Epilepsy Res 2006;70(Supl 1):S5-S10.

  6. Engel J Jr. Report of de ILAE classification core group. Epilepsia 2006;47(9):1558-1568.

  7. Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005;46(6):470-472.

  8. Aviña-Fierro J, Hernández-Aviña D. Encefalopatía epiléptica infantil temprana. Descripción de un caso de síndrome de Ohtahara. Rev Mex Pediatr 2007:743);109-112.

  9. Allan W, Sobel DB. Neonatal intensive care neurology. Semin Pediatr Neurol 2004;11(2):119-128.

  10. Villeneuve N, Ben-Ari Y, Holmes GL, Galarsa JL. Neonatal seizures induced persistent changes in intrinsic propierties of CA1 rat hipocampal cells. Ann Neurol 2000;47(6):729-738.

  11. O´Dell C, Shinnar S. Initiation and discontinuation of antiepileptic drugs. Neurol Clin 2001;19(2):289-311.

  12. Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B. Early development of intractable epilepsy in children: a prospective study. Neurology 2001;56(11):1445-1452.

  13. Zafeiriou DI, Kontopoulos EE, Tsikoulas IG. Adrenocorticotropic hormone and vigabatrin treatment of children with infantile spasms underlying cerebral palsy. Brain Dev 1996;18(6):450-452.

  14. Hirzt DG. First unprovoked seizure. En: Maria BL, editor. Current management in child neurology. London: B.C. Decker; 1999. p. 125-129.

  15. Villanueva VE, Serratosa JM. The course of the catastrophic epilepsies. Rev Neurol 2002;34(6):501-505.

  16. Glauser TA, Pellock JM, Bebin M, Fountain NB, Ritter FJ, Jensen CM, et al. Efficacy and safety of levetiracetam in children with partial seizures: an open trial. Epilepsia 2002;43(5):518-524.

  17. Chugani HT, Chugani DC. Abnormal development and catastrophic epilepsies; the clinical picture and relation to neuroimaging. Int Rev Neurobiol 2001;45:141-157.

  18. French J, Smith M, Faught E, Brown L. Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 1999;52(8): 1540-1545.

  19. Camfield P, Camfield C. Epileptic syndromes in childhood: clinical features, outcome and treatment. Epilepsia 2002;43(Supl 3):27-32.

  20. Baker GA, Currie NG, Light MJ, Schneiderman JH; Top-Can-2 Study Group. The effects of adjunctive topiramate therapy on seizure severity and health-related quality of life in patients with refractory epilepsy: a Canadian study. Seizure 2002;11(1):6-15.

  21. Singh BK, White-Scott S. Role of topiramate in adults with intractable epilepsy, mental retardation, and developmental disabilities. Seizure 2002;11(1):47-50.

  22. Wolf P, Inoue Y. Therapeutic response of absence seizures in patients of an epilepsy clinic for adolescents and adults. J Neurol 1984;231(4):225-229.

  23. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342(5):314-319.

  24. Huang SM, Goodsaid F, Rashman A, Frueh F, Lesko LJ, Aplication of pharmacogenomics in clinical pharmacology. Toxicol Mech Methods 2006;16(2-3):89-99.

  25. Covanis A, Lada C, Skiadas K. Children with rolandic spikes and ictal vomiting: rolandic epilepsy or Panayiotopoulus syndrome. Epileptic Disord 2003;3(5):139-143.

  26. Alva ME. Manual de epilepsia para el pediatra y el médico general. México: Trillas; 2006. p. 19-25.




2020     |     www.medigraphic.com